Trial Profile
A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [beta-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhoea for 24 Weeks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary)
- Indications Dysmenorrhoea
- Focus Registrational; Therapeutic Use
- Sponsors Bayer
- 08 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 23 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 Jul 2013 New trial record